HARTREE-PARTNERS
7.3.2024 08:01:28 CET | Business Wire | Press release
Hartree Partners (UK) Limited (“Hartree”), a wholly owned subsidiary of Hartree Partners LP, which is co-owned by its partners and funds managed by Oaktree Capital Management, announced that it has signed an acquisition agreement for a 50% share in Botres Holding GmbH and its subsidiaries (“Botres”). Headquartered in Graz, Austria, Botres is a key supplier of ultra-modern industrial biogas plants and biorefineries in Austria, Czech Republic, Poland, Italy, Spain and Turkey. Through Bio Scraper, its highly efficient biowaste treatment system, Botres covers the entire processing chain from pre-treatment of all types of organic waste to the efficient production of green energy.
Since being founded in 2012, Botres has built numerous biogas plants across Europe and Turkey and serves some of the world’s largest waste management and infrastructure companies. Botres is led by its founders Dr. Stefan Kromus and Dr. Markus Grasmug, who serve as Managing Directors. Jointly, Dr. Kromus and Dr. Grasmug have over 40 years of experience in the design, development, construction, and operation of waste focused biomethane plants.
Hartree is partnering with Botres to develop a European biomethane production business with a focus on Renewable Energy Directive (RED) compliant feedstocks, which will operate under the Botres brand. The business will focus asset development activities in select countries within the EU and will expand into additional countries on an opportunity-led basis.
“We are excited to partner with Botres, whose innovative technology and proven track record in the biogas space make them an excellent partner for our team as we enter the European biomethane production market. This collaboration directly aligns with Hartree's transition to investing in renewable energy solutions and we look forward to playing a role in providing Europe with clean and reliable biomethane,” said Stephen Hendel, Founding Managing Partner of Hartree Partners LP.
Dr. Kromus said, “We are thrilled to embark on this new chapter with Hartree Partners. This partnership presents a significant opportunity to accelerate the growth of our biomethane production business and solidify Botres' position as a leading player in the industry. We are confident that by combining our expertise and resources, we can deliver exceptional results for our stakeholders and contribute meaningfully to Europe's transition towards a more sustainable energy future.”
About Hartree:
Hartree Partners (UK) Limited is a wholly owned subsidiary of Hartree Partners, LP a limited partnership organised under the laws of Delaware and is a global commodities firm actively trading in oil, gas, power, refined products, shipping, metals and equities. Hartree Partners, LP was established more than 25 years ago and is jointly owned by senior management and funds managed by Oaktree.
Hartree has a unique 25+ year track record in proprietary trading and investing in energy markets across the globe. Our asset development experience ranges from VLCCs, oil, gas and power storage, power generation (conventional & renewable), and gas production facilities, as well as oil refining assets in the US. In Europe Hartree is involved in the UK power market through a portfolio of peak power assets, as well as a portfolio of pan-European renewable generation assets. Hartree acquired a deep knowledge base in the operation of these assets through extensive data analytics and has a wealth of experience in structuring transactions for renewable power and managing intermittent load.
About Botres:
Botres Holding/Botres Global GmbH, headquartered in Graz, Austria, is a leading supplier of modern industrial-scale anaerobic digestion biogas technology, covering the entire process chain from pre-treatment of all types of organic waste, manure and other residues to the efficient production of green energy. Botres was founded in 2012 and emerged from technology development at one of the world’s largest and most successful anaerobic digestion plants in Italy.
Over the past years, Botres has built numerous biogas plants in various European countries, Turkey and Australia. Among Botres’ customers are some of the largest waste management and infrastructure companies in the world. With the development of its highly efficient biowaste treatment system (Bio Scraper), Botres is able to treat basically any type of organic waste. In addition, the technological design and process stability of the plants ensure optimized life cycle expenditures.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240306806400/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom